Weekly cyclophosphamide and alternate-day prednisone: An effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation

Mayo Clinic Proceedings

Volumn 80, Issue 12, 2005, Pages 1578-1582

  Trieu, Young ^a   Trudel, Suzanne ^a,b   Pond, Gregory R ^a   Mikhael, Joseph ^a   Jaksic, Wilfrid ^a   Reece, Donna E ^a   Chen, Christine I ^a   Stewart, A Keith ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ACUTE RESPIRATORY FAILURE; ALOPECIA; ANKLE EDEMA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANADA; CONSTIPATION; CUSHINGOID SYNDROME; DEATH; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE MYELOMA; MYOPATHY; NAUSEA; PNEUMONIA; RELAPSE; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; WEIGHT GAIN;

EID: 28544433393     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.12.1578     Document Type: Article

References (22)

1. Imrie K, Esmail R, Meyer RM, Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med. 2002;136:619-629.
2. Attal M, Harousseau JL, Stoppa AM, et al, Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Eng J Med. 1996;335:91-97.
3. Child JA, Morgan GJ, Davies FE, et al, Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stemcell rescue for multiple myeloma. N Eng J Med. 2003;348:1875-1883.
4. Rivers SL, Patno ME. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. JAMA. 1969;207:1328-1334.
5. Ringborg U, Lewensohn R. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents. Acta Med Scand. 1978;203:276-278.
6. Lenhard RE Jr, Oken MM, Barnes JM, Humphrey RL, Click JH, Silverstein MN. High-dose Cyclophosphamide: an effective treatment for advanced refractory multiple myeloma. Cancer. 1984;53:1456-1460.
7. Ogawa M, Bergsagel DE, McCulloch EA. Chemotherapy of mouse myeloma: quantitative cell cultures predictive of response in vivo. Blood. 1973;41:7-15.
8. Bergsagel DE, Cowan DH, Hasselback R. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent Cyclophosphamide. Can Med Assoc J. 1972;107:851-855.
9. Brandes LJ, Israels LG. Treatment of advanced plasma cell myeloma with weekly Cyclophosphamide and alternate-day prednisone. Cancer Treat Rep. 1982;66:1413-1415.
10. Brandes LJ, Israels LG. Weekly low-dose Cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma. Eur J Haematol. 1987;39:362-368.
11. Wilson K, Shelley W, Belch A, et al. Weekly Cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma. Cancer Treat Rep. 1987;71:981-982.
12. Lenhard RE, Daniels MJ, Oken MM, et al. An aggressive high dose Cyclophosphamide and prednisone regimen for advanced multiple myeloma. Leuk Lymphoma. 1994;13:485-489.
13. de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med. 2001;59:50-56.
14. Richardson PG, Chanan-Khan A, Schlossman RL, et al. Phase II trial of single agent bortezomib (VELCADE®) in patients with previously untreated multiple myeloma (MM) [abstract]. Blood. 2004;104:100a. Abstract 336.
15. Blade J, Samson D, Reece D, et al, Myeloma Subcommittee of the European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102:1115-1123.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Alexanian R, Haut A. Khan AU, et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208:1680-1685.
18. Alexanian R, Yap BS, Bodey GP. Prednisone pulse therapy for refractory myeloma. Blood. 1983;62:572-577.
19. Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79:867-874.
20. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342:364]. N Engl J Med. 1999;341:1565-1571.
21. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc. 2003;78:34-39.
22. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.